Amgen Settles Patent Suit With Amneal on Neupogen Biosimilar

Amgen had claimed that Amneal and Kashiv’s proposed biosimilar version of Neupogen infringed patents for the cancer drug.

• No details were provided in notice of agreement, approved Monday in federal court in Newark, New Jersey
• Neupogen, a white blood cell booster, has been on the market since 1991
• Biosimilars are nearly identical versions of branded biological drugs and are made from living organisms
• Kashiv and Amneal have a license and commercialization agreement in which Kashiv handles development, regulatory filings and manufacturing, and Amneal is responsible for marketing, selling and pricing the Neupogen biosimilar
• Neupogen had U.S. sales of $137 million ...